David Rind, ICER CMO
ICER offers final verdict against Biogen's aducanumab: No proof it works, clear prospect of harm, wildly overpriced
The folks at ICER have crunched the data on aducanumab. The independent drug watchdog brought together a panel of Alzheimer’s experts to review the trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
